Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Rambam Health Care Campus

Status: Unknown

Conditions: Breast Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Lung Adenocarcinoma

Treatments: Other: their will be no intervention in any of the groups, the study is retrospective

Study type: Observational

Funder types: Other

Identifiers

NCT01942629

0298-13ctil

Details and patient eligibility

About

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis.

Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma.

In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma.
• Available histopathological diagnosis of the malignancy.

Exclusion criteria

• Patients with inoperable tumors.
• Patients with second primary tumor.
• Patients with pathological blocks not enough for future slicing.

Trial design

300 participants in 3 patient groups

Lung adenocarcinoma

Description:

This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

Treatment:

Other: their will be no intervention in any of the groups, the study is retrospective

Breast adenocarcinoma

Description:

This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

Treatment:

Other: their will be no intervention in any of the groups, the study is retrospective

Pancreatic ductal adenocarcinoma

Description:

This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.

Treatment:

Other: their will be no intervention in any of the groups, the study is retrospective